Background: With growing emphasis on patient involvement in health technology assessment, there is a need for scientific methods that formally elicit patient preferences. Analytic hierarchy process (AHP) and conjoint analysis (CA) are two established scientific methods -albeit with very different objectives. Objective: The objective of this study was to compare the performance of AHP and CA in eliciting patient preferences for treatment alternatives for stroke rehabilitation. Methods: Five competing treatments for drop-foot impairment in stroke were identified. One survey, including the AHP and CA questions, was sent to 142 patients, resulting in 89 patients for final analysis (response rate 63%). Standard software was used to calculate attribute weights from both AHP and CA. Performance weights for the treatments were obtained from an expert panel using AHP. Subsequently, the mean predicted preference for each of the five treatments was calculated using the AHP and CA weights. Differences were tested using non-parametric tests. Furthermore, all treatments were rank ordered for each individual patient, using the AHP and CA weights. Results: Important attributes in both AHP and CA were the clinical outcome (0.3 in AHP and 0.33 in CA) and risk of complications (about 0.2 in both AHP and CA). Main differences between the methods were found for the attributes 'impact of treatment' (0.06 for AHP and 0.28 for two combined attributes in CA) and 'cosmetics and comfort' (0.28 for two combined attributes in AHP and 0.05 for CA). On a group level, the most preferred treatments were soft tissue surgery (STS) and orthopedic shoes (OS). However, STS was most preferred using AHP weights versus OS using CA weights (p < 0.001). This difference was even more obvious when interpreting the
Background
In recent years, health technology assessment (HTA) processes have expanded beyond those countries dominated with a single payer, and with this expansion renewed attention has been placed on the fundamental evaluation methods that are used. For example, countries such as Germany and the US seem unlikely to embrace traditional methods that involve explicit rationing, including cost-effectiveness analysis. [1] While there has been considerable attention placed on comparative effectiveness research [2] in the US and on efficiency-frontier analysis in Germany, [3] others have emphasized the need for patient involvement in HTA. [4] Patient-centered strategies and methods can be categorized into two types: those that involve patients directly in decision making (whether it be an actual decision-making process or via simulated decision making) and those that aim at the study of patients' needs and preferences for informing HTA. While most progress has been made on the former, with shared decision-making programs and many HTA agencies introducing patient and citizen involvement programs, less progress has been made on the latter.
Many HTA reports are still based on the collection of large amounts of clinical and economic evidence. [4] Patient perceptions are only rarely included, as they are often considered to be anecdotal with limited general value. However, patients may have quite different perceptions on the importance of other criteria, such as risks and impact of the treatment, deemed relevant for implementing health technologies. Therefore, there is a need for techniques that formally assess the intended and unintended consequences of competing medical technologies from the patient's perspective. Several techniques have been introduced to support decision making involving multiple competing criteria. [5] [6] [7] [8] In this study we focus mainly on analytic hierarchy process (AHP) and conjoint analysis (CA), two methods currently being considered by the Institute for Quality and Efficiency in Healthcare in Germany (IQWiG; Institut fu¨r Qualita¨t und Wirtschaftlichkeit im Gesundheitswesen) for the assessment of multiple patient-reported outcomes in their assessment of the relationship between benefits and costs. [7, 9] The AHP is a multi-criteria decision analysis (MCDA) technique that stems from operations research. [10] The AHP has also been applied in many different fields outside healthcare. Within healthcare, it has been used to support shared decision making between patient and doctor, [11] the evaluation and selection of therapies and treatments, [12] the development of medical technologies, [13] and the assessment of health policies. [14] CA is a stated preference evaluation method that often uses the discrete-choice experiment (DCE) format. [7, 15] CA has previously been used within healthcare to examine factors important to patients in the provision of healthcare systems; to estimate the monetary value of improving healthcare to patients; to estimate patient preferences in the doctor-patient relationship; and to estimate preferences for competing treatment alternatives with different qualitative and quantitative outcomes and risks. [7] Multiple empirical studies outside healthcare suggest that the results of AHP and CA have similar predictive validity, [16] [17] [18] although AHP may even perform slightly better. [16, 17] For instance, some studies suggest that AHP is preferred in decision tasks involving more than six criteria. [16] Table I presents the main differences, as published in Mulye et al. [16] Given the many methodological differences between AHP and CA, the choice for one of these methods is largely dependent on the decision context. For instance, it is known that the complexity of MCDA can hinder practical clinical application. [19, 20] The main objective of this paper was to compare AHP and CA, as they are two different methods for weighing multiple clinical outcomes and proposed to study patient preferences. In a previous study comparing these methods in spinal cord injury rehabilitation, we showed that both methods predicted similar preferences for two surgical treatment scenarios. [21] However, in that study, we only compared two treatments, and it was found to be only a moderately difficult decision problem for patients. In this paper, we therefore address a more complex decision problem involving five competing treatments and a more difficult trade-off. We decided to study anklefoot paralysis in stroke, being a very common impairment in stroke. Incidence of stroke is about 795 000 in both the US and Europe, and a vast majority of these patients require foot support. [22] The standard of care is a cheap and reliable ankle-foot orthosis (AFO), at the cost of the daily effort required to attach the splint. Other treatment options involve, for example, more expensive surgical treatment with better clinical outcomes and no additional effort in using assistive devices.
Methods

Defining Treatments and Relevant Attributes
The five treatments considered in rehabilitation of a dropped foot due to paralysis are AFO, orthopedic shoes (OS), neuroprosthetic devices using surface electrodes (s-NP), neuroprosthetic devices using implanted electrodes (i-NP), and soft tissue surgery (STS). [12] Both STS and i-NP require surgery, but may provide additional benefits in terms of efficacy and user-friendliness. The widely adopted standard of care is AFO, as it is cheap, reliable, and effective. To determine the criteria on which clinicians base their treatment decisions, a paper-and-pencil questionnaire was sent to a sample of Dutch physiatrists who were members of a stroke interest group (n = 28; response rate 68%). The questionnaire collected clinical outcome and related criteria relevant for decision making according to the physiatrists. The questionnaire was used to develop a decision tree for the treatment of anklefoot impairment, incorporating six main attributes. This decision tree was then presented to a team of health professionals. The health professionals adapted the tree so that both AHP and CA methods could be used to construct a patient survey (see figure S1 in the Supplemental Digital Content [SDC], http://links.adisonline.com/PBZ/A30).
The Analytic Hierarchy Process (AHP)
The adaptation of the general decision tree for the AHP analysis was a relatively straightforward process. The final decision structure was discussed within a panel of experts and is described in van Til et al. [12] Subsequently, the expert panel judged the AHP decision structure using pairwise comparisons, while supported by the group decisionmaking software Expert Choice. [23] First, the panel provided importance weights for each of the attributes.
1 Second, they judged the (expected) performance of each of the five interventions on these attributes, the performance weights. For collection of patient data, it was decided that patients only had to judge the relative importance of the six main criteria (figure 1), while the performance weights of the expert panel were used to calculate treatment preferences. 1 These attribute weights were obtained to be able to estimate overall treatment performance (not reported in this paper) and to get familiar with the weighing procedure.
made on a scale ranging from -9 to 9, according to the original description of AHP. [10] The scale also used verbal statements ranging from ''the criteria are equally important'' (value of 1) to ''extremely more important'' (value either -9 or 9).
Conjoint Analysis (CA)
The most important difference between AHP and CA is the requirement to be very specific on the formulation of levels in the CA, i.e. different performance levels for the criteria, as the CA survey is built around these level descriptions. The levels generally have to span the range of performance within the treatment alternatives. [24] To determine these attribute levels, all five treatments were described based on the six main criteria of the decision tree. The original idea was that the extremes of these treatment descriptions would then be used as level extremes. However, in the description of the treatments, the expert panel added both quantitative (probability of occurrence) and qualitative descriptions (type of risk or outcome) for the criteria 'risks' and 'outcome'. It was not feasible to include these different descriptions in one attribute, so the CA had two more attributes than the AHP. The attributes had between two and four levels each.
Survey Design
Sawtooth software was used to compile the patient questionnaires. [25] With the balanced overlap method, we reduced the number of treatment scenarios to 82 choice sets. A 'no treatment' or 'opt out' option was not included, because the ankle-foot impairment always requires treatment in these stroke patients. The 80 choice sets were divided over four blocks, which were randomly distributed over the subjects. We included one dominant choice set (presenting a clearly more preferable treatment scenario) in each questionnaire, to test for the ability of the subject to discriminate between a good and bad scenario. If patients failed this test, they were excluded from further analysis. The CA was first introduced to the subjects. They were then asked to choose the treatment that they preferred by ticking the box under their most preferred treatment. Patients were told to weigh the benefits and harms of the different treatments before choosing a treatment. For an example of a choice set (CA) and a pairwise comparison (AHP), see figures S2 and S3 in the SDC.
Overall Patient Questionnaire
The questionnaire was reviewed by the Human Subjects Ethics Review Board of the Roessingh Centre for Rehabilitation and was exempted from formal approval. The questionnaire consisted of two parts. In the first part of the questionnaire, demographic characteristics were collected using a structured answering format. The second part of the questionnaire was introduced to patients by explaining the importance of patient preferences in determining the desirability of treatment in ankle-foot impairment and the relevant treatment characteristics (attributes). In the third part, patients were then asked to fill in the CA and the AHP. The characteristics of the questionnaire and the differences between the AHP and CA sections are presented in table II.
Subjects and Data Collection
Patients with recent ankle-foot impairment were recruited from a regional orthopedic service in the Netherlands. These patients (n = 565) were sent an invitation letter explaining the aim and relevance of the study. A week after the letter was sent, a research assistant called all patients. Of 375 subjects who were reached by telephone, 190 subjects refused to participate, leaving 184 subjects for eligibility screening. Subjects were included if (i) they had nonprogressive central or peripheral disease; (ii) they needed an aid for ankle-foot impairment; and (iii) they were aged between 30 and 75 years. The questionnaire, along with a pre-paid return envelope, was sent to all patients who passed the eligibility screening. A h5 gift coupon was sent to the participant after the questionnaire was returned.
A total of 142 patients were sent the questionnaires.
Statistical Analysis
Descriptive statistics (mean, standard deviation, and frequencies) were used to describe respondent characteristics.
To calculate attribute importance weights in the AHP, the numerical judgments of criteria importance (on a scale from -9 to 9) were placed in a comparison matrix. The reciprocals of the original patient scores were used to complete the matrix. The normalized right principle eigenvector of the matrix was used to calculate the importance weights for the criteria in each individual patient.
In contrast to AHP, CA does not easily provide individual attribute weights. Therefore, hierarchical Bayes was used to estimate part-worth utilities of the attribute levels for each individual patient (Sawtooth HB module [25] ). Subsequently, attribute weights were estimated from the partworth utilities of the attribute levels, as shown in equation 1:
The weight (W) of each attribute (i) was calculated by dividing the range (t i ) of each attribute i (the difference between the least and the most desired part-worth utility) by the sum of the coefficient ranges t i of the eight attributes (i = 1-8).
Following this, treatment preferences were calculated by multiplying the attribute importance weights with the treatment performance weights, as demonstrated in equation 2:
The predicted preference (V) for treatment (a) was calculated based on an additive value function, i.e. the attribute weights (w i ) are multiplied with performance weights (v i ) and summed. In AHP and CA, the predicted treatment preference is obtained by multiplying attribute importance weights with performance weights using an additive value function. The attribute importance weights are obtained from patients, either via pairwise comparison (AHP) or via discrete-choice responses and hierarchical Bayes analysis (CA).
However, treatment performance weights are only obtained from an expert panel using the AHP. [12] To allow proper comparison of AHP and CA, we thus had to transform the AHP performance weights that were to be used in the prediction of treatment preferences based on CA attribute weights. However, as AHP and CA have a different number of attributes, we also had to rescale the AHP performance weights to meet the CA attribute set.
The AHP treatment performance weights were obtained from van Til et al. [12] For each attribute, the five treatments were rank ordered and rank weights were calculated using the method of Edwards and Barron. [26] For example, in our case of five treatments, rank 1 treatment had a weight of 5/15 (0.333), rank 2 had a weight of 4/15 (0.267), and so on. This generates a table of standardized performance weights based on the original AHP weighting obtained from the experts (table III) . [12] These weights were then rescaled to the CA attributes. However, as the number of attributes for AHP and CA was different, we had to make some adaptations. The following assumptions were used (see also figure 1 ). 1. The performance weight for 'result type' and 'success rate' in the CA equals the performance weight of 'result' in the AHP.
2. The weight for 'cosmetics and comfort' in CA is the average of the performance weight 'comfort' and 'cosmetics' in AHP. 3. The weight for 'complication type' and 'complication rate' in CA equals the performance weight of the AHP attribute 'risk'. 4. The weight for 'invasiveness' and 'treatment duration' in CA equals the performance weight of the AHP attribute 'impact of treatment'.
Finally, the standardized treatment performance weights (table III) were transposed to the CA attribute set (table IV). Treatment preference was calculated for each individual patient and then averaged. To test whether there was a difference between the treatment preferences as calculated with AHP and with CA weights, a Wilcoxon signed rank test was used.
Results
Sample Characteristics
After screening and consent, a total of 142 patients were sent the questionnaire. Of those, 89 patients completed both the AHP and CA choice tasks. Three subjects who did not prefer the dominant scenario to the dominated one were excluded from the analysis. Demographic characteristics of these respondents are presented in table V. The mean (SD) age of patients was 60.5 years (10.5) [range 32-77 years]. Patients who did not complete one or both weighting exercises were omitted from further analysis.
Attribute Weights Obtained through AHP and CA
Original attribute weights of the AHP and CA are presented in figure 1 . As the number of attributes was different for AHP and CA, some attributes were combined to allow comparison in the remaining analysis (see the Methods section). From the AHP attribute weights, it can be concluded that 'result' was the most important criterion, followed by 'complications' and 'comfort'. a Some of the attributes use equal performance weights to allow comparison between AHP with six attributes and CA with eight attributes. 'Result type' and 'success rate' are the same as AHP 'result', and 'complication type' and 'complication rate' are the same as AHP 'risk'. In addition, 'cosmetics and comfort' is the average value of AHP 'comfort' and AHP 'cosmetics', and 'invasiveness' and 'treatment duration' are the same rank weights as AHP 'impact of treatment'. AFO = ankle-foot orthosis; AHP = analytic hierarchy process; i-NP = implanted neural prosthesis; OS = orthopedic shoes; s-NP = surface neural prosthesis; STS = soft tissue surgery.
On the other hand, 'probability of outcome' was the most important attribute in the CA study. The greater importance of the attribute 'invasiveness of treatment' in the CA compared with 'impact of treatment' in the AHP was probably caused by the explicit framing of 'surgical procedure' in the CA scenarios. Where 'invasiveness of treatment' was given a high weight in the CA, 'cosmetics and comfort' received higher weights in the AHP. All in all, 'result,' 'ease of use,' and 'complications' received similar weights in AHP and CA. The average predicted preference of the treatment alternatives based on AHP and CA attribute weights is presented in figure 2 . Using the aggregated group averages, there were some differences in predicted treatment preference using the CA and AHP weights. In AHP, the order of the first three treatments was STS (0.277), followed by OS (0.221) and i-NP (0.208). In CA, the first-ranked treatment was OS (0.231), followed by STS (0.221) and AFOs (0.193). The differences are statistically significant at p < 0.001 (difference AHP-CA preference; for STS Z = -8.091; i-NP Z = -7.338; s-NP Z = -7.616; AFO Z = -7.939; and OS Z = -4.453). Another difference between AHP and CA was the range of the weights from the first-to the last-ranked treatment. In AHP, this range was about 0.13, whereas in CA the range was only 0.06. This suggested the preferences obtained from AHP were more extreme compared with CA.
In clinical practice and, for instance, in shared decision making, individual treatment predictions are of more interest than average group preferences. Using AHP and CA weights, the preferred treatments for each individual patient were rank ordered. Figure 3 presents all the data of preferred treatments (rank 1-5). According to figure 3, using AHP weights, 82 patients would have preferred the STS. In contrast, only 37 patients selected STS if we applied CA weights.
In general, we may conclude from figure 3 that AHP predicted a very clear preference for STS in almost all of the patients. Using CA weights gave a less clear picture, with at least three competing treatments for the most preferred treatment (OS, AFO, and STS).
Discussion
As part of the ongoing developments in HTA and the need for more and better involvement of Predicted using AHP weights Predicted using CA weights Fig. 2 . Mean predicted treatment preference using analytic hierarchy process (AHP) and conjoint analysis (CA) attribute weights as presented in figure 1 and the expert panel performance weights as presented in tables III (AHP) and IV (CA). Group averages and standard deviation (indicated by the vertical lines) are presented for all patients. AFO = ankle-foot orthosis; i-NP = implanted neural prosthesis; OS = orthopedic shoes; s-NP = surface neural prosthesis; STS = soft tissue surgery.
patients, many people have studied techniques that deal with the assessment of multiple endpoints. In the health economics literature, CA is the dominating methodology. However, although less known in health economics, the use of AHP in weighing multiple endpoints is increasingly being used and a series of papers [27] [28] [29] have been published in operations research and decision sciences. Both techniques are very useful to formally elicit patient preferences to be incorporated into HTA. Despite their usefulness, many researchers and government bodies such as IQWiG, the UK National Institute for Health and Clinical Excellence (NICE), and the European Medicines Agency (EMA) puzzle over the appropriateness of these methods in cost-benefit and benefit-risk assessment. [8, 30, 31] Several studies have been published comparing CA and AHP. [16] [17] [18] 32, 33] Mulye [16] concluded that AHP has better predictive validity in a hypothetical study. In particular, he recommends AHP in studies involving more than six attributes. Helm et al. [33] also compared AHP and CA as a preference instrument. They concluded that there was a high degree of predictive and convergent validity between the methods, but found AHP slightly better. Kallas et al. [32] compared AHP and CA in measuring food preferences, and did not conclude that any of the methods were superior.
Only two studies reported on the difference between AHP and CA in measuring preferences for clinical endpoints. IJzerman et al. [21] concluded that both methods are able to predict treatment preference in spinal cord injury. A head-to-head comparison of four MCDA methods, including AHP and CA, was performed by van Til et al. [20] The main conclusion in their study was that CA showed more rank reversals than the other three methods. This could be explained by the difference in the range of weights between first-and last-ranked attribute. This appeared to be much smaller for CA, probably because of the indirect estimation of attribute weights compared with the direct elicitation in the other MCDA methods.
Despite the similarities between the methods, several people have criticized AHP as a preference measurement technique. One of the criticisms is that AHP is not well based in multi-attribute utility theory. [34, 35] Although previous studies concluded that both methods were equal, we did find clear differences in this study. While interpreting the attribute weights, there were differences in two attributes. In particular, 'invasiveness' was given much more weight in the CA than in AHP. We expect this was caused by the label 'invasive procedure' in CA, which explicitly referred to a surgical procedure. This was less clear to patients in the AHP study, as patients were only presented an attribute 'impact of treatment'.
Subsequently, we conclude that the average treatment predictions and aggregate treatment ranks (figure 2) using AHP and CA weights were significantly different. Moreover, while interpreting individual treatment preferences, it is obvious that AHP and CA produce different results ( figure 3) . With regard to the outcomes of both methods and the use of treatment alternatives in clinical rehabilitation, the results of the CA seem to have better face validity.
The differences between AHP and CA in this study require further discussion. One of the clear differences is that, in CA, treatment preferences are estimated using scenarios based on attribute levels. The responses are then used to estimate attribute weights. In the AHP, however, attribute weights are obtained using head-to-head comparisons. It is thus very important to use appropriate descriptions of both attributes and levels. Also, in AHP, it is very important to inform patients about the treatment options to consider and the specific characteristics of the treatments.
Another difference that may partly explain the differences between the methods is that, in AHP, the patients only weighted the attributes. The treatment performance weights were obtained from experts in a previous study. [12] We used these performance weights to obtain AHP-and CA-predicted preferences. However, it turned out that the performance judgments obtained from the experts seemed to be biased toward STS. [12] The experts clearly thought STS was the best treatment.
A final comment has to be made on the low response rate. As we had a sampling procedure in which we first identified patients and then checked their eligibility, it may be concluded that the response rate was low. However, despite the low response rate, the sample is still considered to be representative. Furthermore, this study does not intend to generalize its findings on preferences to a wider population. It only compares the methods.
What does this suggest for further use of these methods? In general, both methods have their own advantages and disadvantages for use in benefits assessments. The decision context and multiple practical issues may determine which method to use.
An advantage of CA is that it is more realistic to offer choices from which patients pick their most preferred option. Also, CA can be easily surveyed in large groups of patients, and hence its results can be generalized to a wider population. Another advantage is that CA allows assumptions regarding the utility function, such as interactions between attributes and preference heterogeneity. One point of criticism is that the attribute weight estimations in CA are directly related to the range of the levels. As the range widens, the attributes become more important. This is not true in AHP, as attribute weights and performance weights are obtained independently. Even more importantly, in AHP it is possible to reanalyze the decision tree with an adapted attribute set, e.g. one may remove an attribute and see the impact on overall treatment preference. This is much more difficult to achieve in CA.
Another advantage of the AHP methodology was that the AHP decision tree, as it was defined in this study, did not need much adaptation from a general decision tree, [36] which facilitates understanding by clinicians. Although the forced choice for a treatment scenario is more realistic and closer to actual decision making, the design of a CA survey required more flexibility and cognitive effort of healthcare professionals. Therefore, we find that AHP is easy to use and quite flexible for a number of healthcare decisions. Compared with CA, the mathematics is easy to understand and it does not require a lot of sophisticated modeling. One important assumption to address in AHP is the requirement that the attributes used should not be related. This is particularly the case in IQWiG's benefits assessment, [9] where AHP is proposed to weigh multiple patient-reported endpoints. In clinical practice, many of these endpoints are related and it requires some effort to address this dependency in the AHP. Some design adaptations and statistical solutions are proposed and tested outside healthcare, but this has not yet been transferred to healthcare applications.
For further use of these methods, some recommendations can be given. In this study, treatments were described according to treatment characteristics deemed relevant to patients. However, the attributes were determined by health professionals. It may be questioned whether that is appropriate. In AHP, it may be difficult for patients to determine the importance of an attribute when they are not familiar with the range of possible outcomes for that particular attribute. It may, therefore, be recommended to either start by asking for performance weights to obtain a clearer picture of the range of alternatives, or by providing accurate and detailed information on the alternatives before doing the choice tasks.
Conclusion
Although multiple studies have demonstrated that AHP and CA have equal predictive and convergent validity, we did find differences between AHP and CA in predicting treatment preference. On the group level, both methods seemed to result in a different rank order of the treatments. Individual treatment predictions varied even more widely between AHP and CA. We suggest that these differences were caused by the framing of attributes and levels, as well as the differences in elicitation of performance judgments. Therefore, both methods are useful in determining patient preferences. The decision context and several practical considerations, such as ease of application, should determine which method to use.
